Shots:
Intellia Therapeutics completed enrollment in the global P-III (HAELO) study evaluating lonvo-z for treating HAE, finishing within 9mos. since the first patient was dosed in Jan 2025, with nearly half of the participants enrolled from the US
The study P-III (HAELO) study will evaluate the efficacy and safety of lonvo-z in ≥60 adults and…
